Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma
Status:
Recruiting
Trial end date:
2024-06-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to show that the addition of COMPOUND 2055269, an
immunotherapeutic drug, to Folfox chemotherapy will improve the pathologic complete response
rate in patients with locally advanced rectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Ali Shamseddine
Collaborators:
Merck KGaA Merck KGaA, Darmstadt, Germany Phoenix Clinical Research